M&A Deal Summary

GSK Acquires CNS

On October 9, 2006, GSK acquired life science company CNS for 566M USD

Acquisition Highlights
  • This is GSK’s 5th transaction in the Life Science sector.
  • This is GSK’s 14th largest (disclosed) transaction.
  • This is GSK’s 5th transaction in the United States.
  • This is GSK’s 1st transaction in Minnesota.

M&A Deal Summary
Date 2006-10-09
Target CNS
Sector Life Science
Buyer(s) GSK
Deal Type Add-on Acquisition
Deal Value 566M USD
Advisor(s) CG Sawaya Partners (Financial)

Target

CNS

Minneapolis, Minnesota, United States
CNS, the manufacturer of Breathe Right(R) nasal strips and FiberChoice(R) dietary fiber supplements.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

GSK

Brentford, United Kingdom
Category Company
Founded 1715
Sector Life Science
Employees70,212
Revenue 30.3B GBP (2023)
DESCRIPTION
Entrance to a GlaxoSmithKline facility in Morristown, New Jersey.
Entrance to a GlaxoSmithKline facility in Morristown, New Jersey.

GSK is a multinational pharmaceutical, biologics, vaccines and consumer healthcare company. GSK was founded in 1715 and is based in Brentford, United Kingdom.

DEAL STATS #
Overall 6 of 32
Sector (Life Science) 5 of 26
Type (Add-on Acquisition) 4 of 24
State (Minnesota) 1 of 1
Country (United States) 5 of 19
Year (2006) 1 of 2
Size (of disclosed) 14 of 28
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2005-05-02 Corixa

Seattle, Washington, United States

Corixa Corporation (Nasdaq: CRXA), a developer of innovative products that regulate immunity, based in Seattle, WA (USA).

Buy €233M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2006-12-08 Domantis

Cambridge, United Kingdom

Domantis has pioneered the next generation of antibody therapy, which is based on the smallest functional binding units of human antibodies. These units, termed domain antibodies (dAbs), may be administered in inhaled, topical, and, potentially, oral formulations as well as by injection and infusion. The Domantis technology also enables dAbs to serve as building blocks for therapeutics simultaneously directed at more than one disease target.

Buy £230M
Mergr

Product

Company

Legal